Skip to main content
Fig. 2 | Retrovirology

Fig. 2

From: HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial

Fig. 2

Anti-Tat humoral immune response elicited in study participants. a Percentage of responders for anti-Tat Abs (see “Methods” section) in vaccinees (n = 99) or placebos (n = 100). The absolute number of vaccines/placebos developing anti-Tat Ig subclasses are reported on the top of each histogram. Statistical significant differences were detected between vaccinees and placebos for each Ig and for total response (p < 0.0001, Chi square test). b Percentage of responders for anti-Tat Abs stratified according to the presence of one or more Ab isotype in vaccinees (n = 99) or placebos (n = 100). The absolute number of vaccines/placebos developing one or more Ab isotype are reported on the top of each histogram. Statistical significant differences were detected between vaccinees and placebos (p < 0.0001, Chi square test). c IgM, IgG and IgA Ab mean titers (with standard error) in responders (vaccinees: n = 79 for IgM, n = 95 for IgG and n = 75 for IgA; placebos: n = 9 for IgM, n = 12 for IgG and n = 6 for IgA). Significant differences were detected between vaccinees and placebos for anti-Tat IgG Abs from week 12 to week 48 (Student’s t test)

Back to article page

Retrovirology

ISSN: 1742-4690

Contact us